Does Spironolactone Have a Dose-Dependent Effect on Left Ventricular Remodeling in Patients with Preserved Left Ventricular Function After an Acute Myocardial Infarction?

被引:16
作者
Vatankulu, Mehmet Akif [1 ]
Bacaksiz, Ahmet [1 ]
Sonmez, Osman [1 ]
Alihanoglu, Yusuf [2 ]
Koc, Fatih [3 ]
Demir, Kenan [4 ]
Gul, Enes Elvin [4 ]
Turfan, Murat [1 ]
Tasal, Abdurrahman [1 ]
Kayrak, Mehmet [4 ]
Yazici, Mehmet [4 ]
Ozdemir, Kurtulus [4 ]
机构
[1] Bezmialem Vakif Univ, Fac Med, Dept Cardiol, TR-34010 Istanbul, Turkey
[2] Pamukkale Univ, Dept Cardiol, Fac Med, Denizli, Turkey
[3] Gaziosmanpasa Univ, Dept Cardiol, Fac Med, Tokat, Turkey
[4] Selcuk Univ, Dept Cardiol, Fac Med, Konya, Turkey
关键词
Aldosterone; Myocardial infarction; Preserved ejection fraction; Remodeling; Spironolactone; PRIMARY CORONARY ANGIOPLASTY; MITRAL DECELERATION TIME; HEART-FAILURE; DYSFUNCTION; EPLERENONE; MARKER;
D O I
10.1111/1755-5922.12006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The aim of this study was to investigate the effects of spironolactone on left ventricular (LV) remodeling in patients with preserved LV function following acute myocardial infarction (AMI). Methods and Results Successfully revascularized patients (n=186) with acute ST elevation MI (STEMI) were included in the study. Patients were randomly divided into three groups, each of which was administered a different dose of spironolactone (12.5, 25mg, or none). Echocardiography was performed within the first 3days and at 6months after MI. Echocardiography control was performed on 160 patients at a 6-month follow-up. The median left ventricular ejection fraction (LVEF) increased significantly in all groups, but no significant difference was observed between groups (P=0.13). At the end of the sixth month, the myocardial performance index (MPI) had improved in each of the three groups, but no significant difference was found between groups (F=2.00, P=0.15). The mean LV peak systolic velocities (S-m) increased only in the control group during the follow-up period, but there is no significant difference between groups (F=1.79, P=0.18). The left ventricular end-systolic volume index (LVESVI) and the left ventricular end-diastolic volume index (LVEDVI) did not change significantly compared with the basal values between groups (F=0.05, P=0.81 and F=1.03, P=0.31, respectively). Conclusion In conclusion, spironolactone dosages of up to 25mg do not augment optimal medical treatment for LV remodeling in patients with preserved cardiac functions after AMI.
引用
收藏
页码:224 / 229
页数:6
相关论文
共 15 条
[1]  
[Anonymous], 2005, HEART DIS STROKE STA
[2]  
Antman Elliott M, 2004, J Am Coll Cardiol, V44, P671, DOI 10.1016/j.jacc.2004.07.002
[3]   Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction [J].
Bolognese, L ;
Carrabba, N ;
Parodi, G ;
Santoro, GM ;
Buonamici, P ;
Cerisano, G ;
Antoniucci, D .
CIRCULATION, 2004, 109 (09) :1121-1126
[4]   Left ventricular remodeling after primary coronary angioplasty - Patterns of left ventricular dilation and long-term prognostic implications [J].
Bolognese, L ;
Neskovic, AN ;
Parodi, G ;
Cerisano, G ;
Buonamici, P ;
Santoro, GM ;
Antoniucci, D .
CIRCULATION, 2002, 106 (18) :2351-2357
[5]   Doppler-derived mitral deceleration time - An early strong predictor of left ventricular remodeling after reperfused anterior acute myocardial infarction [J].
Cerisano, G ;
Bolognese, L ;
Carrabba, N ;
Buonamici, P ;
Santoro, GM ;
Antoniucci, D ;
Santini, A ;
Moschi, G ;
Fazzini, PF .
CIRCULATION, 1999, 99 (02) :230-236
[6]   Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction [J].
Hayashi, M ;
Tsutamoto, T ;
Wada, A ;
Tsutsui, T ;
Ishii, C ;
Ohno, K ;
Fujii, M ;
Taniguchi, A ;
Hamatani, T ;
Nozato, Y ;
Kataoka, K ;
Morigami, N ;
Ohnishi, M ;
Kinoshita, M ;
Horie, M .
CIRCULATION, 2003, 107 (20) :2559-2565
[7]   A CLINICAL-TRIAL OF THE ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR TRANDOLAPRIL IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL-INFARCTION [J].
KOBER, L ;
TORPPEDERSEN, C ;
CARLSEN, JE ;
BAGGER, H ;
ELIASEN, P ;
LYNGBORG, K ;
VIDEBEK, J ;
COLE, DS ;
AUCLERT, L ;
PAULY, NC ;
ALIOT, E ;
PERSSON, S ;
CAMM, AJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1670-1676
[8]   Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [J].
Pitt, B ;
Remme, W ;
Zannad, F ;
Neaton, J ;
Martinez, F ;
Roniker, B ;
Bittman, R ;
Hurley, S ;
Kleiman, J ;
Gatlin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14) :1309-1321
[9]   The effect of spironolactone on morbidity and mortality in patients with severe heart failure [J].
Pitt, B ;
Zannad, F ;
Remme, WJ ;
Cody, R ;
Castaigne, A ;
Perez, A ;
Palensky, J ;
Wittes, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) :709-717
[10]   Improving outcomes in post-acute myocardial infarction heart failure: Incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade [J].
Pitt, Bertram ;
Fonarow, Gregg C. ;
Gheorghiade, Mihai ;
Deedwania, Prakash C. ;
Duprez, Daniel A. .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (10A) :26F-33F